Jacobson Pharma Corporation Ltd
HKEX:2633
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.3), the stock would be worth HK$1 (11% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.5 | HK$1.13 |
0%
|
| 3-Year Average | 1.3 | HK$1 |
-11%
|
| 5-Year Average | 0.9 | HK$0.68 |
-40%
|
| Industry Average | 2.6 | HK$1.97 |
+74%
|
| Country Average | 1.1 | HK$0.84 |
-26%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
HK$2.5B
|
/ |
Oct 2025
HK$1.5B
|
= |
|
|
HK$2.5B
|
/ |
Mar 2026
HK$1.6B
|
= |
|
|
HK$2.5B
|
/ |
Mar 2027
HK$1.7B
|
= |
|
|
HK$2.5B
|
/ |
Mar 2028
HK$1.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
J
|
Jacobson Pharma Corporation Ltd
HKEX:2633
|
2.3B HKD | 1.5 | 7.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 12.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 5.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 4.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 4.8 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 4.2 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.7 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 2.4 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 2.4 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1.1 |
| 70th Percentile | 2.8 |
| Max | 59 382.6 |
Other Multiples
Jacobson Pharma Corporation Ltd
Glance View
Jacobson Pharma Corp. Ltd. engages in the provision of generic drugs for both public and private sectors. The company employs 1,723 full-time employees The company went IPO on 2016-09-21. The firm runs its business via two segments. Generic Drugs segment develops, manufactures and distributes a host of off-patent medicine for various therapeutic uses. Currently the activities in this regard are primarily carried out in Hong Kong. Proprietary Chinese Medicines segment develops, manufactures and distributes Chinese medicines. Currently the activities in this regard are primarily carried out in Hong Kong.
